May 25, 2017
Achaogen Announces Pricing of Public Offering of Common Stock
SOUTH SAN FRANCISCO, Calif., May 25, 2017 (GLOBE NEWSWIRE) -- Achaogen, Inc. (AKAO), a late-stage biopharmaceutical company discovering and developing innovative antibacterials addressing multi-drug resistant ...

May 24, 2017
BioTime Co-CEO Dr. Michael West to Deliver Presentation as Part of Biotech Panel at Mauldin Economics’ Strategic Investment Conference on May 24
BioTime, Inc. (NYSE MKT: BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today announced that Co-Chief Executive Officer Michael D. West, Ph.D., ...

May 24, 2017
Lysogene Selects Brammer Bio to Produce GM1 Gangliosidosis Gene Therapy Product
Lysogene (LYS.PA) (FR0013233475 – LYS), a leading, biopharmaceutical company pioneering gene therapy technologies to treat central nervous system diseases, today announced that it has entered ...

May 24, 2017
Kamada Presents Updated Data from Phase 2 Clinical Trial of Inhaled Alpha-1-Antitrypsin for Treatment of Alpha-1 Antitrypsin Deficiency at 2017 American Thoracic Society International Conference
NESS ZIONA, Israel, May 24, 2017 (GLOBE NEWSWIRE) -- Kamada Ltd. (KMDA) (KMDA.TA), a plasma-derived protein therapeutics company focused on orphan indications, today announced that ...

May 24, 2017
Paratek Pharmaceuticals to Present New Data from Omadacycline Development Program at ASM Microbe 2017
BOSTON, May 24, 2017 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (PRTK) announced today that data from its omadacycline clinical and microbiology programs will be presented ...

May 24, 2017
Sierra Oncology to Present Innovative Clinical Trial Enhancements Leveraging Chk1 Synthetic Lethality in Two Posters at ASCO Annual Meeting
VANCOUVER , May 24, 2017 /CNW/ - Sierra Oncology, Inc. (SRRA), a clinical stage drug development company focused on advancing next generation DNA Damage Response ...

May 24, 2017
TRACON Doses First Patient in Phase 1/2 Study of TRC253 in Patients with Prostate Cancer
SAN DIEGO, May 24, 2017 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted ...

May 23, 2017
Selexis SA and OSE Immunotherapeutics Sign Commercial License Agreement to Further Advance Development of OSE's Interleukin Receptor 7 Antagonist
GENEVA & NANTES, France--(BUSINESS WIRE) -- Selexis SA and OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnémo: OSE) announced today the signing of a commercial license agreement that ...

May 23, 2017
Onxeo Announces 10th Positive DSMB Recommendation to Continue Livatag® ReLive Phase III Trial in HCC
PARIS, May 23, 2017 (GLOBE NEWSWIRE) -- Onxeo S.A. (Euronext Paris:ONXEO) (NASDAQ Copenhagen:ONXEO), a clinical-stage biotechnology company specializing in the development of innovative drugs for ...

May 23, 2017
Albireo Announces Proposed Public Offering of Common Stock
BOSTON, May 23, 2017 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, announced today ...

May 23, 2017
Achaogen Announces Proposed Public Offering of Common Stock
SOUTH SAN FRANCISCO, Calif., May 23, 2017 (GLOBE NEWSWIRE) -- Achaogen, Inc. (AKAO), a late-stage biopharmaceutical company discovering and developing innovative antibacterials addressing multi-drug resistant ...

May 23, 2017
Plazomicin Granted FDA Breakthrough Therapy Designation
May 23, 2017 SOUTH SAN FRANCISCO, Calif., May 23, 2017 (GLOBE NEWSWIRE) -- Achaogen, Inc. (AKAO), a late-stage biopharmaceutical company developing innovative antibacterials addressing multi-drug ...

May 23, 2017
OSE Immunotherapeutics Strengthens R&D Team with Appointment of Two Senior Talented Immunologists
NANTES, France, May 22, 2017 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics SA (ISIN:FR0012127173); (Mnémo:OSE) announced today the appointment of Aurore Morello, Ph.D., as Immunology Researcher, and ...

May 23, 2017
Positive Clinical Data on INOpulse® Presented at the American Thoracic Society 113th International Conference
WARREN, N.J., May 22, 2017 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (BLPH), a clinical-stage biotherapeutics company, today announced the presentation of new clinical data from a ...

May 23, 2017
Windtree Receives SBIR Grant in Continued Support of AEROSURF® Phase 2b Clinical Trial
WARRINGTON, Pa., May 22, 2017 /PRNewswire/ -- Windtree Therapeutics, Inc. (WINT), a biotechnology company focused on developing aerosolized KL4 surfactant therapies for respiratory diseases, today ...

May 23, 2017
Positive Phase 2a results with microdoses of dasiglucagon support use in a dual-hormone artificial pancreas system
Copenhagen, May 23, 2017 - Zealand Pharma ("Zealand") announces positive results from a Phase 2a trial following administration of the multiple-dose version of dasiglucagon in adult ...

May 23, 2017
BioTime to Present at 16th National Life Sciences and Biotechnology Week (MIXiii BIOMED)
ALAMEDA, Calif.--(BUSINESS WIRE)-- BioTime, Inc. (NYSE MKT: BTX and TASE: BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today announced that BioTime, ...

May 23, 2017
Aeglea BioTherapeutics Provides AEB1102 Program and Corporate Update
AUSTIN, Texas, May 23, 2017 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc., (AGLE) a biotechnology company committed to developing enzyme-based therapeutics in the field of amino ...

May 22, 2017
INNATE PHARMA : IPH4102: Completion of the dose escalation part of the phase I trial - Data to be presented at ICML in June 2017 in Lugano
Innate Pharma SA (the "Company" - Euronext Paris: FR0010331421 - IPH) today announced that it has completed the dose escalation part of its ongoing Phase ...

May 22, 2017
Kiadis to Host Key Opinion Leader Meeting on Addressing the Risks of Haloidentical HSCT in Blood Cancer
Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company developing innovative products to make bone marrow ...

May 22, 2017
BrainStorm to Present at Cell & Gene Exchange Conference in Washington DC
HACKENSACK, N.J. and PETACH TIKVAH, Israel, May 22, 2017 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (BCLI), a leading developer of adult stem cell technologies for neurodegenerative ...

May 22, 2017
iCAD to Participate in Two Upcoming Investor Conferences
NASHUA, N.H., May 22, 2017 (GLOBE NEWSWIRE) -- iCAD, Inc. (ICAD), an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy for the ...

May 22, 2017
Zogenix Announces Presentation of ZX008 Mechanism of Action Data at Annual Meeting of Society of Biological Psychiatry
EMERYVILLE, Calif., May 22, 2017 (GLOBE NEWSWIRE) -- Zogenix, Inc. (ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system ...

May 22, 2017
Rockwell Medical Issues Letter to Shareholders Explaining Why Electing Mark Ravich Could Do Lasting Harm
WIXOM, Mich., May 22, 2017 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (RMTI) today mailed a letter to its shareholders in connection with the Company’s upcoming ...

May 22, 2017
Onconova Announces Multiple Presentations at the 22nd Congress of the European Hematology Association
NEWTOWN, Pa., May 22, 2017 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (ONTX), a Phase 3-stage biopharmaceutical company focused on discovering and developing novel products to ...

May 21, 2017
Results of ATHOS-3 Phase 3 Study of LJPC-501 Published in The New England Journal of Medicine
SAN DIEGO--(BUSINESS WIRE) -- La Jolla Pharmaceutical Company (LJPC) (La Jolla) today announced that results of the ATHOS-3 (Angiotensin II for the Treatment of High-Output ...

May 19, 2017
OSE Immunotherapeutics to Present at Annual Sachs Immuno-Oncology: BD&L and Investment Forum
NANTES, France, May 18, 2017 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics SA(ISIN:FR0012127173) (Mnémo:OSE) announced today that the Company will present at the upcoming “Annual Sachs Immuno-Oncology: ...

May 19, 2017
DelMar Pharmaceuticals Announces Third Quarter Fiscal Year 2017 Financial Results
VANCOUVER, British Columbia and MENLO PARK, Calif., May 18, 2017 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (DMPI) ("DelMar" and the "Company"), a biopharmaceutical company focused on the ...

May 19, 2017
Santhera Provides Update on Timeline for Application of Raxone® in Duchenne Muscular Dystrophy in Europe
Liestal, Switzerland, May 19, 2017 - Santhera Pharmaceuticals, a specialty pharmaceutical company focused on the development of innovative treatments for rare mitochondrial and neuromuscular diseases, announces ...

May 18, 2017
Why won’t VCs return your calls and emails?
You have this breakthrough invention. You know it will change the world. But passion alone isn’t enough. You need moolah to fuel your innovations. And ...

May 18, 2017
Arena Pharmaceuticals to Host Key Opinion Leader Event on Pulmonary Arterial Hypertension (PAH) on May 25 in New York City
SAN DIEGO, May 18, 2017 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (ARNA), today announced that it will host a key opinion leader (KOL) event for investors focused ...

May 18, 2017
Onconova Therapeutics to Present a Poster Session Relating to Intravenous Rigosertib at the 2017 American Society of Clinical Oncology Annual Meeting
NEWTOWN, Pa., May 18, 2017 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (ONTX), a Phase 3-stage biopharmaceutical company focused on discovering and developing novel products to ...

May 18, 2017
Oramed to Present at Conferences Next Week
JERUSALEM, May 18, 2017 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today ...

May 18, 2017
Albireo Announces Plans for Phase 3 Clinical Program of A4250 in Patients with PFIC
BOSTON, May 18, 2017 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced ...

May 18, 2017
Aurinia Doses First Patient in AURORA Phase 3 Clinical Trial of Voclosporin in Lupus Nephritis
VICTORIA, British Columbia--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH/TSX:AUP) (“Aurinia” or the “Company”), a clinical stage biopharmaceutical company focused on the global immunology market, today announced that ...

May 18, 2017
Advaxis to Host Investor & Analyst Day on June 12
PRINCETON, N.J.--(BUSINESS WIRE)--Advaxis, Inc. (ADXS), a late-stage biotechnology company developing cancer immunotherapies, today announced that it will host its annual Investor & Analyst Day on ...

May 18, 2017
MediWound Announces Changes to its Board of Directors
YAVNE, Israel, May 18, 2017 (GLOBE NEWSWIRE) -- MediWound Ltd. (MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn ...

May 17, 2017
Eiger Announces Results Demonstrating Benefit of Ubenimex and Leukotriene B4 (LTB4) Modulation in Experimental Lymphedema
PALO ALTO, Calif., May 17, 2017 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc., (EIGR) today announced publication in Science Translational Medicine (STM) the results of extensive preclinical studies ...

May 17, 2017
Zealand reports results for the first three months of 2017 (unaudited)
Copenhagen, May 17, 2017 - Zealand Pharma A/S ("Zealand") (Company reg. No. 20 04 50 78) announces financial results in line with guidance and continued ...

May 16, 2017
Arena Pharmaceuticals to Present Phase 1 Data on Ralinepag for Treatment of Pulmonary Arterial Hypertension at the American Thoracic Society 2017 International Conference
SAN DIEGO, May 16, 2017 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (ARNA) will present detailed Phase 1 data on ralinepag (APD811), the Company's next-generation, oral, selective prostacyclin ...

May 16, 2017
LYSOGENE REINFORCES ITS MANAGEMENT TEAM WITH THE NOMINATION OF PHILIPPE MENDELS-FLANDRE AS CHIEF OPERATING OFFICER
Lysogene (FR0013233475 – LYS), a leading clinical-stage biopharmaceutical company specializing in gene therapy technology applied to central nervous system diseases, today announced the nomination of ...

May 16, 2017
Rockwell Medical Encourages Shareholders Not to Be Misled by Richmond Brothers
WIXOM, Mich., May 16, 2017 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (RMTI) today mailed a letter to its shareholders in connection with the Company’s upcoming ...

May 16, 2017
Aeglea BioTherapeutics to Present at the UBS 2017 Global Healthcare Conference
AUSTIN, Texas, May 16, 2017 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc., (AGLE) a biotechnology company committed to developing enzyme-based therapeutics in the field of amino ...

May 16, 2017
Prothena Announces Appointment of Sarah Noonberg, MD, PhD as Chief Medical Officer
DUBLIN, Ireland, May 16, 2017 (GLOBE NEWSWIRE) -- Prothena Corporation plc (PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of ...

May 16, 2017
BioDelivery Sciences Reports First Quarter 2017 Financial Results and Provides Corporate Update
RALEIGH, N.C., May 15, 2017 /PRNewswire/ -- BioDelivery Sciences International, Inc. (BDSI) today reported financial results for the first quarter ended March 31, 2017 and ...

May 16, 2017
OSE Immunotherapeutics Presents New Data on Anti-SIRPa (Effi-DEM), the Checkpoint Inhibitor blocking Pro-Tumor and Suppressor Myeloid Cells at “Advances in Immuno-Oncology Congress,” London, May 15-16, 2017
NANTES, France, May 15, 2017 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics SA(ISIN:FR0012127173) (Mnémo:OSE) announced today that the Company presented in oral session significant data on Selective ...

May 16, 2017
LifeSci Venture Partners’ Paul Yook to Moderate Panel at MedCity INVEST Conference
NEW YORK, May 15, 2017 (GLOBE NEWSWIRE) -- LifeSci Advisors today announced that Paul Yook, General Partner, LifeSci Venture Partners, will moderate the opening panel ...

May 16, 2017
Pernix Therapeutics Reports First Quarter 2017 Financial Results and Provides Business Update
MORRISTOWN, N.J., May 15, 2017 (GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings, Inc. (PTX) (“Pernix” or the “Company”), a specialty pharmaceutical company, today announced financial results ...

May 16, 2017
Windtree Therapeutics Reports First Quarter 2017 Financial Results and Provides Key Business Updates
WARRINGTON, Pa., May 15, 2017 /PRNewswire/ -- Windtree Therapeutics, Inc. (WINT), a biotechnology company focused on developing aerosolized KL4 surfactant therapies for respiratory diseases, today reported ...

May 16, 2017
Threshold Pharmaceuticals Reports First Quarter Financial Results
MENLO PARK, Calif., May 15, 2017 (GLOBE NEWSWIRE) -- Threshold Pharmaceuticals, Inc. (THLD) today reported financial results for the first quarter ended March 31, 2017, ...

May 16, 2017
Santhera to Present Data and Host Symposium on Pulmonary Function in Duchenne Muscular Dystrophy at the American Thoracic Society 113th Annual Conference
Liestal, Switzerland, May 16, 2017 - Santhera Pharmaceuticals, a specialty pharmaceutical company focused on the development of innovative treatments for rare mitochondrial and neuromuscular diseases, announces ...

May 16, 2017
BrainStorm Initiated Technology Transfer to City of Hope for U.S. Production of NurOwn® for Phase 3 ALS Study
HACKENSACK, N.J., PETACH TIKVA, Israel and DUARTE, Calif., May 16, 2017 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (BCLI), a leading developer of adult stem cell technologies ...

May 16, 2017
Kamada Reports 2017 First Quarter Financial Results
NESS ZIONA, Israel, May 16, 2017 (GLOBE NEWSWIRE) -- Kamada Ltd.  (KMDA) (KMDA.TA), a plasma-derived protein therapeutics company focused on orphan indications, today announced financial ...

May 16, 2017
Palatin Technologies, Inc. Reports Third Quarter Fiscal Year 2017 Results; Teleconference and Webcast to be held on May 16, 2017
CRANBURY, N.J., May 16, 2017 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases ...

May 16, 2017
Altimmune Promotes Dr. Sybil Tasker to Chief Medical Officer
GAITHERSBURG, Md., May 16, 2017 (GLOBE NEWSWIRE) -- Altimmune, Inc. (ALT), a clinical-stage immunotherapeutics company, today announced the promotion of Sybil Tasker, M.D., FACP, FIDSA, ...

May 16, 2017
Albireo Announces Two New U.S. Patents Allowed for A4250 with Term into 2031
BOSTON, May 16, 2017 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced ...

May 16, 2017
CTD Holdings to Host Webinar to Provide Update on Trappsol(R) Cyclo(TM) Drug Development Program for Treatment of Niemann-Pick Disease Type C
ALACHUA, FL--(Marketwired - May 16, 2017) - CTD Holdings, Inc. (CTDH), a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of disease, ...

May 15, 2017
INNATE PHARMA : First quarter 2017 report
Marseille, France, May 15, 2017, 7:00 AM CEST -- Innate Pharma SA (the "Company" - Euronext Paris: FR0010331421 - IPH) today announced its revenues and cash ...

May 15, 2017
Ignyta Granted Breakthrough Therapy Designation for Entrectinib by U.S. Food and Drug Administration
SAN DIEGO--(BUSINESS WIRE)-- Ignyta, Inc. (RXDX), a biotechnology company focused on precision medicine in oncology, today announced that the U.S. Food and Drug Administration (FDA) has ...

May 15, 2017
Aradigm Announces First Quarter 2017 Financial Results
Aradigm Corporation (ARDM) (the “Company”) today announced financial results for the first quarter and three months ended March 31, 2017. ...

May 15, 2017
BrainStorm Announces First Quarter 2017 Financial Results and Provides Corporate Update
HACKENSACK, N.J. and PETACH TIKVAH, Israel, May 15, 2017 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (BCLI), a leading developer of adult stem cell technologies for neurodegenerative ...

May 15, 2017
VBL Therapeutics Announces First Quarter 2017 Financial Results
TEL AVIV, Israel, May 15, 2017 (GLOBE NEWSWIRE) -- VBL Therapeutics (VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class ...

May 15, 2017
Aurinia Reports First Quarter 2017 Financial Results, Announces Initiation of Phase III Aurora Clinical Trial, and Provides Operational Highlights
VICTORIA, British Columbia--(BUSINESS WIRE)-- Aurinia Pharmaceuticals Inc. (AUPH) (AUP.TO) (“Aurinia” or the “Company”) has released its financial results for the first quarter ended March 31, 2017. ...

May 15, 2017
Eiger BioPharmaceuticals Completes Enrollment of Phase 2 LIBERTY Study of Ubenimex in Pulmonary Arterial Hypertension
PALO ALTO, Calif., May 15, 2017 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (EIGR), focused on the development and commercialization of targeted therapies for rare diseases, announced completion ...

May 15, 2017
Alcobra Announces Leadership Update
TEL AVIV, Israel, May 15, 2017 (GLOBE NEWSWIRE) -- Alcobra Ltd. (ADHD), an emerging pharmaceutical company focused on the development of new medications to treat ...

May 15, 2017
Minerva Announces Outcome of End-of-Phase 2 Meeting With FDA
WALTHAM, Mass., May 15, 2017 (GLOBE NEWSWIRE) -- Following a recent "end-of-Phase 2" meeting with the U.S. Food and Drug Administration (FDA), Minerva Neurosciences, Inc. ...

May 15, 2017
Minerva Provides Update on Phase 3 Design and Development Strategy for MIN-101
WALTHAM, Mass., May 15, 2017 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central ...

May 15, 2017
Onconova Therapeutics, Inc. Reports Recent Business Highlights and First Quarter 2017 Financial Results
NEWTOWN, Pa., May 15, 2017 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing novel small ...

May 15, 2017
Advaxis Provides Phase 1 Data of Higher Dose Axalimogene Filolisbac
PRINCETON, N.J.--(BUSINESS WIRE)-- UPDATED — Advaxis, Inc. (ADXS), a biotechnology company developing cancer immunotherapies, today published online a poster previously presented at the National Cancer Research ...

May 11, 2017
Ohr Pharmaceutical Announces Fiscal Second Quarter 2017 Earnings
NEW YORK, May 11, 2017 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (OHRP), a clinical-stage pharmaceutical company developing novel therapies for ophthalmic diseases, today reported results ...

May 11, 2017
STRATA Skin Sciences Reports First Quarter 2017 Financial Results
HORSHAM, Pa., May 11, 2017 (GLOBE NEWSWIRE) --  (SSKN) STRATA Skin Sciences, Inc. (“STRATA”) a medical technology company in Dermatology and Plastic Surgery dedicated to ...

May 11, 2017
CymaBay Reports First Quarter 2017 Financial Results and Provides Corporate Update
NEWARK, Calif., May 11, 2017 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (CBAY), a clinical-stage biopharmaceutical company developing therapies to treat specialty and orphan diseases with ...

May 11, 2017
TRACON Pharmaceuticals Announces Publication in Blood of Preclinical Data Indicating Activity of TRC105 in Acute Myeloid Leukemia and B-cell Acute Lymphoblastic Leukemia
SAN DIEGO, May 11, 2017 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted ...

May 11, 2017
BioLife Solutions Announces Q1 2017 Financial Results
BOTHELL, Wash., May 11, 2017 /PRNewswire/ -- BioLife Solutions, Inc. (BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation ...

May 11, 2017
Capnia Provides Corporate Update and Reports First Quarter 2017 Financial Results
REDWOOD CITY, Calif., May 11, 2017 (GLOBE NEWSWIRE) -- Capnia, Inc. (CAPN), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, ...

May 11, 2017
Ohr Pharmaceutical Announces Appointment of Hon. Mike Ferguson as Chairman of the Board of Directors
NEW YORK, May 11, 2017 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (OHRP), a clinical-stage pharmaceutical company developing novel therapies for ophthalmic diseases, today announced the ...

May 11, 2017
DelMar Formalizes Collaboration with PRA Health Sciences for Phase 3 Trial of VAL-083 in Recurrent Glioblastoma Multiforme (GBM)
VANCOUVER, British Columbia and MENLO PARK, Calif., May 11, 2017 /PRNewswire/ -- DelMar Pharmaceuticals (DMPI) ("DelMar" and the "Company"), a biopharmaceutical company focused on developing new ...

May 11, 2017
VALNEVA Reports Strong Q1 Revenue Growth and Positive EBITDA; Reaffirms Financial Guidance and Pipeline Outlook for 2017
Lyon (France), May 11, 2017 - Valneva SE ("Valneva" or "the Company"), a fully integrated, commercial stage biotech company focused on developing innovative lifesaving vaccines, ...

May 11, 2017
TiGenix to present at Bank of America Merrill Lynch 2017 Healthcare Conference in Las Vegas
Leuven (BELGIUM) - May 11, 2017, 07:00h CEST - TiGenix NV (Euronext Brussels and NASDAQ: TIG), an advanced biopharmaceutical company focused on exploiting the anti-inflammatory ...

May 11, 2017
Zealand Pharma discloses amylin as the biological target under their 2014 agreement with Boehringer Ingelheim
Copenhagen, May 11, 2017 - Zealand Pharma A/S ("Zealand") and Boehringer Ingelheim GmbH have demonstrated that the novel long-acting amylin analogue ZP4982 prevents the development ...

May 11, 2017
OncoSec to Host Third Quarter Financial Conference Call on June 1, 2017
SAN DIEGO, May 11, 2017 /PRNewswire/ -- OncoSec Medical Incorporated ("OncoSec") (ONCS), a company developing DNA-based intratumoral cancer immunotherapies, announced today that the Company will ...

May 11, 2017
VBL Therapeutics Presents Data on VB-111 in Combination with Checkpoint Inhibitor at the 20th Annual ASGCT Meeting
TEL AVIV, Israel, May 11, 2017 (GLOBE NEWSWIRE) -- VBL Therapeutics (VBLT) today announced new preclinical data indicating that treatment with ofranergene obadenovec (VB-111) augments ...

May 11, 2017
BioTime Presents Retinal Restoration Data at ARVO
ALAMEDA, Calif.--(BUSINESS WIRE)-- BioTime, Inc. (NYSE MKT: BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today announced that a poster related to the ...

May 11, 2017
Vermillion Reports First Quarter 2017 Results
AUSTIN, Texas, May 11, 2017 /PRNewswire/ -- Vermillion, Inc. (VRML), a bio-analytical solutions company focused on gynecologic disease, reported on its financial results for the first ...

May 11, 2017
BIOPHYTIS: First patient-in in the United States and opening of 2 clinical centers for the SARA-OBS study on Sarcopenia
PARIS, May 11, 2017 (GLOBE NEWSWIRE) -- BIOPHYTIS (Alternext Paris:ALBPS), a biotechnology company specialized in the development of drug candidates to treat ageing diseases, has ...

May 11, 2017
Aimmune Therapeutics Enrolls First Patient in RAMSES (ARC007), a Phase 3 Clinical Trial of AR101 for the Treatment of Peanut Allergy
BRISBANE, Calif.--(BUSINESS WIRE)-- Aimmune Therapeutics, Inc. (AIMT), today announced the enrollment of its first patient in the Phase 3 RAMSES (ARC007) clinical trial of AR101 for ...

May 11, 2017
Catalyst Biosciences Reports First Quarter 2017 Financial Results and Provides Corporate Update
SOUTH SAN FRANCISCO, Calif., May 11, 2017 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (CBIO), a clinical-stage biopharmaceutical company focused on developing novel medicines to address ...

May 10, 2017
Onxeo Announces Allowance of U.S. Patent for Livatag® in Hepatocellular Carcinoma
PARIS, May 10, 2017 (GLOBE NEWSWIRE) -- Onxeo S.A. (Euronext Paris:ONXEO) (NASDAQ Copenhagen:ONXEO), a clinical-stage biotechnology company specializing in the development of innovative drugs for ...

May 10, 2017
BioTime, Inc. Reports First Quarter Results and Recent Corporate Accomplishments
BioTime, Inc. (NYSE MKT and TASE: BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today reported financial results for the first quarter ...

May 10, 2017
Albireo Reports First Quarter 2017 Financial Results
BOSTON, May 10, 2017 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today reported ...

May 10, 2017
SciClone Reports First Quarter 2017 Financial Results
FOSTER CITY, Calif., May 10, 2017 /PRNewswire/ -- SciClone Pharmaceuticals, Inc. (SCLN) today reported financial results for the quarter ended March 31, 2017. Revenues: In ...

May 10, 2017
DURECT Corporation Announces First Quarter 2017 Financial Results and Provides Corporate Update
CUPERTINO, Calif., May 10, 2017 /PRNewswire/ -- DURECT Corporation (DRRX) today announced financial results for the three months ended March 31, 2017 and provided a corporate ...

May 10, 2017
TRACON Pharmaceuticals Reports First Quarter Financial Results and Provides Corporate Update
SAN DIEGO, May 10, 2017 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted ...

May 10, 2017
TherapeuticsMD Announces Presentation at Bank of America Merrill Lynch 2017 Healthcare Conference on May 16
BOCA RATON, Fla.--(BUSINESS WIRE)-- TherapeuticsMD, Inc. (NYSE MKT: TXMD), an innovative women’s healthcare company, today announced that the company’s CEO Robert Finizio will present at the ...

May 10, 2017
TiGenix to present at the Crohn's and Colitis Foundation's Novel Technologies in Inflammatory Bowel Disease workshop in New York
Leuven (BELGIUM) - May 10, 2017, 07:00h CEST - TiGenix NV (Euronext Brussels and NASDAQ: TIG), an advanced biopharmaceutical company focused on exploiting the anti-inflammatory ...

May 10, 2017
OncoSec Announces Clinical Collaboration with Merck to Evaluate Combination of ImmunoPulse® IL-12 and KEYTRUDA® (pembrolizumab) for Metastatic Melanoma
SAN DIEGO, May 10, 2017 /PRNewswire/ -- OncoSec Medical Incorporated ("OncoSec") (ONCS), a company developing DNA-based intratumoral cancer immunotherapies, has entered a clinical trial collaboration and ...

May 10, 2017
Sierra Oncology Receives Clearance to Enhance Ongoing Clinical Trials for SRA737
VANCOUVER, May 10, 2017 /PRNewswire/ - Sierra Oncology, Inc. (SRRA), a clinical stage drug development company focused on advancing next generation DNA Damage Response (DDR) ...

May 10, 2017
Bellerophon Announces $3.0 Million Registered Direct Offering
WARREN, N.J., May 10, 2017 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (BLPH), a clinical-stage biotherapeutics company, today announced that it has entered into a definitive agreement ...

May 10, 2017
Heron Therapeutics Reports Financial Results for the Three Months Ended March 31, 2017 and Recent Corporate Progress
SAN DIEGO--(BUSINESS WIRE) -- Heron Therapeutics, Inc. (HRTX) (the Company or Heron), a commercial-stage biotechnology company focused on developing novel best-in-class treatments to address some of ...

May 10, 2017
STRATA Skin Sciences, Inc. Announces the Appointment of James L. Coyne to its Board of Directors
HORSHAM, Pa., May 10, 2017 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (SSKN) (“STRATA”), a medical technology company in Dermatology and Plastic Surgery dedicated to ...

May 10, 2017
Rockwell Medical Files Investor Presentation
WIXOM, Mich., May 10, 2017 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (RMTI) today announced that it has filed an investor presentation with the Securities and ...

May 10, 2017
Neovacs and Lupus Europe Join Voices on World Lupus Day
PARIS and BOSTON, May 10, 2017 (GLOBE NEWSWIRE) -- Neovacs (Alternext Paris:ALNEV), a leader in active immunotherapies for the treatment of autoimmune diseases, and Lupus ...

May 9, 2017
Ignyta Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Ignyta, Inc. (RXDX) ("Ignyta"), a biotechnology company focused on precision medicine in oncology, today announced the closing of its previously announced underwritten public offering of ...

May 9, 2017
Arena Pharmaceuticals Provides Corporate Update and Reports First Quarter 2017 Financial Results
SAN DIEGO, May 9, 2017 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (ARNA), a biopharmaceutical company focused on developing novel, small molecule drugs across multiple therapeutic areas, today ...

May 9, 2017
Rockwell Medical Reports First Quarter Results
WIXOM, Mich., May 09, 2017 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease ...

May 9, 2017
Ocera Therapeutics Reports First Quarter 2017 Financial Results and Provides Clinical Update
REDWOOD CITY, Calif. and RESEARCH TRIANGLE PARK, N.C., May 09, 2017 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. (OCRX), a clinical stage biopharmaceutical company focused on ...

May 9, 2017
Foamix Reports First Quarter 2017 Financial Results and Provides Business Update
REHOVOT, Israel, May 9, 2017 /PRNewswire/ -- Foamix Pharmaceuticals Ltd.(FOMX) ("Foamix Pharmaceuticals" or the "Company"), a clinical stage specialty pharmaceutical company focused on developing and commercializing ...

May 9, 2017
Heron Therapeutics to Present at the Bank of America Merrill Lynch 2017 Healthcare Conference
Heron Therapeutics, Inc. (HRTX), a commercial-stage biotechnology company focused on developing novel best-in-class treatment solutions to address some of the biggest unmet patient needs, announced ...

May 9, 2017
Prothena Reports First Quarter 2017 Financial Results and Provides R&D Update
DUBLIN, Ireland, May 09, 2017 (GLOBE NEWSWIRE) -- Prothena Corporation plc (PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of ...

May 9, 2017
Mateon Provides Corporate Update and Reports First Quarter 2017 Financial Results
SOUTH SAN FRANCISCO, Calif., May 08, 2017 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (MATN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment ...

May 9, 2017
Scottish Medicines Consortium Approves Santhera's Raxone® (idebenone) for Restricted Use in Patients with LHON within NHS Scotland
Liestal, Switzerland, May 9, 2017 - Santhera Pharmaceuticals (SIX: SANN) announces approval by the Scottish Medicines Consortium for restricted use of Raxone® (idebenone) in patients with LHON, ...

May 9, 2017
Addex ADX71441 Demonstrates Preclinical Analgesic Effects
Geneva, Switzerland, 9 May 2017 - Addex Therapeutics (ADXN.SW) announced today positive results from multiple preclinical studies of ADX71441, a positive allosteric modulator (PAM) of ...

May 9, 2017
Gemphire Announces First Quarter 2017 Financial Results and Provides Corporate Update
LIVONIA, Mich., May 09, 2017 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for cardiometabolic disorders, ...

May 9, 2017
Sierra Oncology Reports First Quarter 2017 Results
VANCOUVER, May 9, 2017 /PRNewswire/ - Sierra Oncology, Inc. (SRRA), a clinical stage drug development company focused on advancing next generation DNA Damage Response (DDR) therapeutics ...

May 9, 2017
BioTime Announces New Positive Data from OpRegen® Trial in Dry-AMD
ALAMEDA, Calif.--(BUSINESS WIRE)-- BioTime, Inc. (NYSE MKT:BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today announced new data from the Phase I/IIa clinical ...

May 9, 2017
Ohr Pharmaceutical to Announce Fiscal Second Quarter 2017 Results on May 11
NEW YORK, May 09, 2017 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (OHRP), a clinical-stage pharmaceutical company developing novel therapies for ophthalmic diseases, today announced that ...

May 9, 2017
Pharma Industry Veteran Dr. George Milne Joins Aurinia’s Board of Directors
VICTORIA, British Columbia--(BUSINESS WIRE)-- Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) (“Aurinia” or the “Company”), a clinical stage biopharmaceutical company focused on the global immunology market, today ...

May 9, 2017
Aimmune Therapeutics to Present at the Bank of America Merrill Lynch Healthcare Conference on Tuesday, May 16
BRISBANE, Calif.--(BUSINESS WIRE) -- Aimmune Therapeutics, Inc. (AIMT), a biopharmaceutical company developing CODIT™ (Characterized Oral Desensitization ImmunoTherapy) treatments for life-threatening food allergies, today announced that CEO ...

May 9, 2017
Aeglea BioTherapeutics Provides Corporate Update and Reports First Quarter 2017 Financial Results
AUSTIN, Texas, May 09, 2017 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc., (AGLE) a biotechnology company committed to developing enzyme-based therapeutics in the field of amino ...

May 9, 2017
Rockwell Medical Shareholders Express Support for the Election of David Domzalski
WIXOM, Mich., May 09, 2017 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (RMTI) today released several statements of support from shareholders in connection with the Company’s ...

May 8, 2017
Pernix Therapeutics to Report First Quarter 2017 Financial Results on Monday, May 15
MORRISTOWN, N.J., May 08, 2017 (GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings, Inc. (PTX) a specialty pharmaceutical company, announced today that the Company will report financial ...

May 8, 2017
Aimmune Therapeutics Announces First Quarter 2017 Financial Results
Aimmune Therapeutics, Inc. (AIMT), a biopharmaceutical company developing CODIT™ (Characterized Oral Desensitization ImmunoTherapy) treatments for life-threatening food allergies, today announced financial results for first quarter ...

May 8, 2017
Achaogen Reports First Quarter 2017 Financial Results and Provides Corporate Update
SOUTH SAN FRANCISCO, Calif., May 08, 2017 (GLOBE NEWSWIRE) -- Achaogen, Inc. (AKAO), a late-stage biopharmaceutical company discovering and developing innovative antibacterials addressing multi-drug resistant ...

May 8, 2017
Paratek Announces Completion of Enrollment for Oral-only Omadacycline Phase 3 Skin Study, Top-line Data Expected in Mid-July
BOSTON, May 08, 2017 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (PRTK), a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon ...

May 8, 2017
DURECT and Sandoz have Signed a $293 Million Development and Commercialization Agreement for POSIMIR® (SABER®-Bupivacaine) Covering the United States
CUPERTINO, Calif., May 8, 2017 /PRNewswire/ -- DURECT Corporation (DRRX) today announced a development and commercialization agreement with Sandoz AG, a division of Novartis (NVS), ...

May 8, 2017
BioTime Co-CEO Dr. Michael D. West to Present at World Advanced Therapies & Regenerative Medicine Congress on May 17 and 19
ALAMEDA, Calif.--(BUSINESS WIRE)-- BioTime, Inc. (NYSE MKT: BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today announced that Co-Chief Executive Officer Michael D. ...

May 8, 2017
MediWound Reports First Quarter 2017 Financial Results
YAVNE, Israel, May 08, 2017 (GLOBE NEWSWIRE) -- MediWound Ltd. (MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn ...

May 8, 2017
TherapeuticsMD Receives Complete Response Letter from FDA for TX-004HR New Drug Application
BOCA RATON, Fla.--(BUSINESS WIRE)-- TherapeuticsMD, Inc. (NYSE MKT: TXMD), an innovative women’s healthcare company, today announced that it received a Complete Response Letter (CRL) from the ...

May 8, 2017
Eiger Announces Presentation of Prevalence Data of Hepatitis Delta Virus (HDV) Infection in the U.S. at Digestive Disease Week (DDW) in Chicago
PALO ALTO, Calif., May 8, 2017 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc., (EIGR) today announced HDV/HBV co-infection prevalence data from an International Classification of Diseases (ICD) analysis ...

May 8, 2017
Lipocine Announces Financial and Operational Results for the First Quarter 2017
SALT LAKE CITY, May 08, 2017 (GLOBE NEWSWIRE) -- Lipocine Inc. (LPCN), a specialty pharmaceutical company, today announced financial results for the first quarter ended ...

May 8, 2017
DelMar Presents New Mechanism of Action Data for its Lead Agent VAL-083 in Temozolomide-Resistant Glioblastoma Multiforme (GBM) at the World Federation of Neuro-Oncology Societies (WFNOS)
VANCOUVER, British Columbia and MENLO PARK, Calif., May 8, 2017 /PRNewswire/ -- DelMar Pharmaceuticals (DMPI) ("DelMar" and the "Company"), a biopharmaceutical company focused on developing new ...

May 8, 2017
Kamada to Host First Quarter 2017 Financial Results Conference Call on May 16
NESS ZIONA, Israel, May 08, 2017 (GLOBE NEWSWIRE) -- Kamada Ltd. (KMDA) (KMDA), a plasma-derived protein therapeutics company focused on orphan indications, announced today that ...

May 8, 2017
Rexahn Pharmaceuticals to Present RX-3117 Clinical Data at the American Society of Clinical Oncology (ASCO) 2017 Annual Meeting
ROCKVILLE, Md., May 08, 2017 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN), a clinical stage biopharmaceutical company developing innovative, targeted therapeutics for the treatment ...

May 5, 2017
Erin Andrews to Participate in Cervical Cancer Educational Forum Hosted by Sylvester Comprehensive Cancer Center and Gilda’s Club, Sponsored by Advaxis
HOLLYWOOD, Fla.-- (BUSINESS WIRE) -- Erin Andrews, host of ABC’s Dancing with the Stars, reporter with Fox Sports and cervical cancer survivor, will be a special ...

May 5, 2017
Alcobra Provides Update on Cancellation of Extraordinary Meeting Called by Brosh Group
TEL AVIV, Israel, May 05, 2017 (GLOBE NEWSWIRE) -- Alcobra Ltd. (ADHD), an emerging pharmaceutical company focused on the development of new medications to treat ...

May 5, 2017
Achaogen Receives Investment from the Bill & Melinda Gates Foundation to Develop Antibodies Against Gram-Negative Bacteria
SOUTH SAN FRANCISCO, Calif., May 05, 2017 (GLOBE NEWSWIRE) -- Achaogen, Inc. (AKAO), a late-stage biopharmaceutical company developing novel antibacterials addressing multidrug-resistant (MDR) gram-negative infections, ...

May 5, 2017
First-Ever European Analysis of Electronic Brachytherapy Using the Xoft System for Endometrial and Cervical Cancer Treatment to be Presented at European Society for Radiotherapy & Oncology Meeting
NASHUA, N.H. and VIENNA, Austria, May 05, 2017 (GLOBE NEWSWIRE) -- (Booth #4330) - iCAD, Inc. (ICAD), an industry-leading provider of advanced image analysis, workflow solutions and ...

May 5, 2017
Rockwell Medical Schedules First Quarter 2017 Earnings Call
WIXOM, Mich., May 05, 2017 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease ...

May 5, 2017
Rexahn Effects 1-for-10 Reverse Stock Split
ROCKVILLE, Md., May 05, 2017 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN) (“Rexahn” or the “Company”), a clinical stage biopharmaceutical company developing innovative, targeted ...

May 4, 2017
Gemphire to Host Key Opinion Leader Lunch on the Evolving NASH Landscape
LIVONIA, Mich., May 04, 2017 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for cardiometabolic disorders, ...

May 4, 2017
Zogenix Provides Corporate Update and Reports First Quarter 2017 Financial Results
EMERYVILLE, Calif., May 04, 2017 (GLOBE NEWSWIRE) -- Zogenix, Inc. (ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system ...

May 4, 2017
Mirati Therapeutics Reports First Quarter 2017 Financial Results
SAN DIEGO, May 4, 2017 /PRNewswire/ -- Mirati Therapeutics, Inc. (MRTX), a clinical stage oncology biotechnology company, reported financial results for the first quarter 2017 ...

May 4, 2017
TiGenix Cx601 positive long-term results to be presented at Digestive Disease Week
Leuven (BELGIUM) - May 4, 2017, 07:00h CEST - TiGenix NV (Euronext Brussels and NASDAQ: TIG), an advanced biopharmaceutical company focused on exploiting the anti-inflammatory ...

May 4, 2017
Addex ADX71441 Preclinical Results for Treatment of Alcohol Use Disorder Published in Journal of Psychopharmacology
Geneva, Switzerland, 4 May 2017 - Addex Therapeutics (ADXN.SW) announced today that the results of a preclinical study evaluating ADX71441 in animal models of alcohol use ...

May 4, 2017
SciClone Pharmaceuticals To Report First Quarter 2017 Financial Results On May 10, 2017
FOSTER CITY, Calif., May 4, 2017 /PRNewswire/ -- SciClone Pharmaceuticals, Inc. (SCLN) today announced that it plans to report financial results for the first quarter ...

May 4, 2017
BioLife Solutions to Report First Quarter 2017 Financial Results and Provide Business Update on May 11, 2017
BOTHELL, Wash., May 4, 2017 /PRNewswire/ -- BioLife Solutions, Inc. (BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storageand cryopreservation freeze media ...

May 4, 2017
Paratek Pharmaceuticals, Inc. Reports First Quarter 2017 Financial Results and Provides Clinical Update
BOSTON, May 04, 2017 (GLOBE NEWSWIRE) --  Paratek Pharmaceuticals, Inc. (PRTK), a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon ...

May 4, 2017
Evogene Files Annual Report for the Year Ended December 31, 2016
REHOVOT, Israel, May 04, 2017 (GLOBE NEWSWIRE) -- Evogene Ltd. (EVGN) (EVGN), a leading company for the improvement of crop productivity and economics for food, feed ...

May 4, 2017
Neovacs to Present Clinical Development Update On IFNα Kinoid in Dermatomyositis
PARIS and BOSTON, May 04, 2017 (GLOBE NEWSWIRE) -- Neovacs (Alternext Paris:ALNEV), a leader in active immunotherapies for the treatment of autoimmune diseases, today announced ...

May 4, 2017
Eiger BioPharmaceuticals to Host Key Opinion Leader Event Addressing Need for Novel Mechanisms in the Treatment of Pulmonary Arterial Hypertension (PAH) on May 10th in New York City
PALO ALTO, Calif., May 4, 2017 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (EIGR), focused on the development and commercialization of targeted therapies for rare diseases, will host ...

May 4, 2017
CymaBay to Report First Quarter 2017 Financial Results on Thursday, May 11
NEWARK, Calif., May 04, 2017 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for specialty and orphan diseases ...

May 4, 2017
Minerva Neurosciences Reports First Quarter 2017 Financial Results and Business Updates
WALTHAM, Mass., May 04, 2017 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central ...

May 4, 2017
Rockwell Medical Mails Letter to Shareholders Profiling Independent Director Nominee David Domzalski
WIXOM, Mich., May 04, 2017 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (NASDAQ:RMTI) today mailed a letter to its shareholders in connection with the Company's upcoming ...

May 4, 2017
Onconova Therapeutics, Inc. to Provide Corporate Update and First Quarter 2017 Financial Results
NEWTOWN, Pa., May 04, 2017 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing novel products ...

May 4, 2017
Rexahn Pharmaceuticals Reports First Quarter 2017 Financial Results and Provides Corporate Update
ROCKVILLE, Md., May 04, 2017 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN), a clinical stage biopharmaceutical company developing innovative, targeted therapeutics for the treatment ...

May 4, 2017
Immune Pharmaceuticals Announces Private Placement of up to $3.4 Million Read more: http://www.nasdaq.com/press-release/immune-pharmaceuticals-announces-private-placement-of-up-to-34-million-20170504-01088#ixzz4g7TwxwKz
  NEW YORK, May 4, 2017 /PRNewswire/ -- Immune Pharmaceuticals Inc. (Nasdaq:IMNP) ("Immune" or the "Company") today announced that it has entered into definitive agreements with ...

May 3, 2017
LifeSci Advisors Expands Corporate Access Team with Appointment of Tara Hartigan
NEW YORK, May 03, 2017 (GLOBE NEWSWIRE) -- LifeSci Advisors, LLC (the "Company" or "LifeSci"), the leading international investor relations and corporate communications firm dedicated ...

May 2, 2017
Revolt Against Sky-High Drug Prices Prompts a Pioneer to Cash Out
Entrepreneur Jeffrey Aronin said a few years ago he hoped to eventually sell Marathon Pharmaceuticals LLC, which he controls and runs, for billions of dollars, ...

May 2, 2017
Perrigo Says Investigators Searched Its Offices in Generic-Drug Probe
Perrigo Co. PRGO -5.09% said Tuesday its offices were searched by investigators conducting a federal probe of price collusion in the generic-drug industry. ...